Cited by 3,848Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Treatment and Pharmacology

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, Malcolm J., Goldstein, David, Hamm, John, Figer, Arie, Hecht, Joel R., Gallinger, Steven, Au, Heather J., Murawa, Pawel, Walde, David, Wolff, Robert A., Campos, Daniel, Lim, Robert, Ding, Keyue, Clark, Gary, Voskoglou-Nomikos, Theodora, Ptasynski, Mieke, Parulekar, Wendy·2007·Journal of Clinical Oncology

DOI 10.1200/jco.2006.07.9525

Open this paper in CoChat — free account

Abstract

Purpose: Patients with advanced pancreatic cancer have a poor prognosis and there have been no improvements in survival since the introduction of gemcitabine in 1996. Pancreatic tumors often overexpress human epidermal growth factor receptor type 1 (HER1/EGFR) and this is associated with a worse prognosis. We studied the effects of adding the HER1/EGFR-targeted agent erlotinib to gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer. Patients and Methods: Patients were randomly assigned 1:1 to receive standard gemcitabine plus erlotinib (100 or 150 mg/d orally) or gemcitabine plus placebo in a double-blind, international phase III trial. The primary end point was overall survival. Results: A total of 569 patients were randomly assigned. Overall survival based on an intent-to-treat analysis was significantly prolonged on the erlotinib/gemcitabine arm with a hazard ratio (HR) of 0.82 (95% CI, 0.69 to 0.99; P = .038, adjusted for stratification factors; median 6.24 months v 5.91 months). One-year survival was also greater with erlotinib plus gemcitabine (23% v 17%; P = .023). Progression-free survival was significantly longer with erlotinib plus gemcitabine with an estimated HR of 0.77 (95% CI, 0.64 to 0.92; P = .004). Objective response rates were not significantly different between the arms, although more patients on erlotinib had disease stabilization. There was a higher incidence of some adverse events with erlotinib plus gemcitabine, but most were grade 1 or 2. Conclusion: To our knowledge, this randomized phase III trial is the first to demonstrate statistically significantly improved survival in advanced pancreatic cancer by adding any agent to gemcitabine. The recommended dose of erlotinib with gemcitabine for this indication is 100 mg/d.

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.9525

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Cancer Statistics, 2005
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J., Hickey, H., Beger, H. G., Fernández‐Cruz, L., Dervenis, C., LACAINE, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,709
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citation
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Flagged first, then by citations

Show all 49 references

1 of the 49 references couldn’t be matched to a known paper.

Sorted by citations

Items 901–1,000 of 1,008

Pancreatic ductal adenocarcinoma: the latest on diagnosis, molecular profiling, and systemic treatments
Bugazia, D., Al-Najjar, E., Esmail, A., Abdelrahim, S., Abboud, K., Abdelrahim, A., Umoru, G., Rayyan, H. A., Abudayyeh, A., Moustafa, A. A., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1386699 · Cited by 51
Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors
Michl, M., Haug, A. R., Jakobs, T., Paprottka, P. M., Hoffmann, R., Bartenstein, P., Boeck, S. H., Haas, M., Laubender, R. P., & Heinemann, V. (2013) · Oncology · doi:10.1159/000355821 · Cited by 50
Adjuvant therapy in pancreatic cancer
Jones, O. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14733 · Cited by 50
Intermittent Erlotinib in Combination with Pemetrexed: Phase I Schedules Designed to Achieve Pharmacodynamic Separation
Davies, A. M., Ho, C., Beckett, L. A., Lau, D. H., Scudder, S., Lara, P. N., Perkins, N., & Gandara, D. R. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a94b08 · Cited by 49
SnapShot: Pancreatic Cancer
Han, H., & Hoff, D. D. V. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.008 · Cited by 50
Clinical biomarkers of angiogenesis inhibition
Brown, A. P., Citrin, D. E., & Camphausen, K. A. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9143-x · Cited by 49
Radiofrequency Ablation of Liver Metastasis in Patients with Locally Controlled Pancreatic Ductal Adenocarcinoma
Park, J. B., Kim, Y. H., Kim, J., Chang, H.-M., Kim, T. W., Kim, S. C., Kim, P. N., & Han, D. J. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.01.080 · Cited by 50
Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
Dong, P., Fang, Z., Zhang, Y., Ge, G., Mao, Y., Zhu, L., Qu, Y.-Q., Li, W., Wang, L., Liu, C., et al. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.218 · Cited by 50
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)
Aranda, E., Manzano, J. L., Rivera, F., Galán, M., Valladares‐Ayerbes, M., Pericay, C., Safont, M. J., Mendez, M. J., Irigoyen, A., Arrivi, A., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr560 · Cited by 50
MM-398 (Nanoliposomal Irinotecan): Emergence of a Novel Therapy for the Treatment of Advanced Pancreatic Cancer
Carnevale, J. C., & Ko, A. H. (2015) · Future Oncology · doi:10.2217/fon.15.333 · Cited by 51
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Simon, N. C., & FitzGerald, D. (2016) · Toxins · doi:10.3390/toxins8050137 · Cited by 50
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
Abdel‐Wahab, R., Varadhachary, G. R., Bhosale, P., Wang, X., Fogelman, D. R., Shroff, R. T., Overman, M. J., Wolff, R. A., & Javle, M. M. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0616-2 · Cited by 50
Self-citation
Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer
Yotsumoto, F., Fukami, T., Yagi, H., Funakoshi, A., Yoshizato, T., Kuroki, M., & Miyamoto, S. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01671.x · Cited by 50
Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer
Galanis, E., Carlson, S. K., Foster, N. R., Lowe, V. J., Quevedo, F., McWilliams, R. R., Grothey, A. F., Jatoi, A., Alberts, S. R., & Rubin, J. (2008) · Molecular Therapy · doi:10.1038/mt.2008.29 · Cited by 50
Systemic cancer therapy: Evolution over the last 60 years
Dy, G. K., & Adjei, A. A. (2008) · Cancer · doi:10.1002/cncr.23651 · Cited by 52
Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines
von der Heyde, S., Bender, C., Henjes, F., Sonntag, J., Korf, U., & Beißbarth, T. (2014) · BMC Systems Biology · doi:10.1186/1752-0509-8-75 · Cited by 50
Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar–ductal metaplasiaPreprint
Liu, X., Pitarresi, J. R., Cuitiño, M. C., Kladney, R. D., Woelke, S. A., Sizemore, G. M., Nayak, S. G., Egriboz, O., Schweickert, P. G., Yu, L., et al. (2016) · Genes & Development · doi:10.1101/gad.283499.116 · Cited by 50
New targeted therapies in pancreatic cancer
Seicean, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i20.6127 · Cited by 48
GSK3β and β-Catenin Modulate Radiation Cytotoxicity in Pancreatic Cancer
Watson, R. L., Spalding, A. C., Zielske, S. P., Morgan, M. A., Kim, A. C., Bommer, G. T., Eldar-Finkelman, H., Giordano, T. J., Fearon, E. R., Hammer, G. D., et al. (2010) · Neoplasia · doi:10.1593/neo.92112 · Cited by 51
Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes
Bleeker, F. E., Lamba, S., Rodolfo, M., Scarpa, A., Leenstra, S., Vandertop, W. P., & Bardelli, A. (2009) · Human Mutation · doi:10.1002/humu.20927 · Cited by 49
Risk Factors and Therapeutic Targets in Pancreatic Cancer
Wörmann, S. M., & Algül, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00282 · Cited by 51
S-1 in the treatment of pancreatic cancer
Sudo, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15110 · Cited by 49
Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer
Bao, G.-Q., Shen, B., Pan, C., Zhang, Y., Shi, M.-M., & Peng, C. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2013.06.241 · Cited by 52
Buccal adhesive nanofibers containing human growth hormone for oral mucositis
Choi, J. S., Han, S., Hyun, C., & Yoo, H. S. (2015) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33487 · Cited by 49
Multicenter Phase II Study of Gemcitabine and S-1 Combination Therapy (GS Therapy) in Patients With Metastatic Pancreatic Cancer
Ueno, H., Okusaka, T., Furuse, J., Yamao, K., Funakoshi, A., Boku, N., Ohkawa, S., Yokosuka, O., Tanaka, K., Moriyasu, F., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr090 · Cited by 49
Targeted therapies for pancreatic cancer
Danovi, S. A., Wong, H. H., & Lemoine, N. R. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn027 · Cited by 49
Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro
Lee, J., Lee, J., Kim, S. J., & Kim, J. H. (2016) · Oncology Reports · doi:10.3892/or.2016.4598 · Cited by 49
Percutaneous Radiofrequency Ablation of Unresectable Locally Advanced Pancreatic Cancer: Preliminary Results
D’Onofrio, M., Crosara, S., Robertis, R. D., Butturini, G., Salvia, R., Paiella, S., Bassi, C., & Mucelli, R. P. (2016) · Technology in Cancer Research & Treatment · doi:10.1177/1533034616649292 · Cited by 49
A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer
Schwartzberg, L. S., Arena, F. P., Bienvenu, B. J., Kaplan, E. H., Camacho, L. H., Campos, L. T., Waymack, J. P., Tagliaferri, M. A., Chen, M. M., & Li, D. (2017) · Journal of Cancer · doi:10.7150/jca.15407 · Cited by 49
Immunotherapy in pancreatic adenocarcinoma—overcoming barriers to response
Rosenberg, A. J., & Mahalingam, D. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.13 · Cited by 48
Clinical Effectiveness and Potential Survival Benefit of US-Guided High-Intensity Focused Ultrasound Therapy in Patients with Advanced-Stage Pancreatic Cancer
Marinova, M., Huxold, H. C., Henseler, J., Mücke, M., Conrad, R., Rolke, R., Ahmadzadehfar, H., Rauch, M., Fimmers, R., Lüchters, G., et al. (2018) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/a-0591-3386 · Cited by 49
Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
Sheahan, A. V., Biankin, A. V., Parish, C. R., & Khachigian, L. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25085 · Cited by 49
Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis
Mackay, T. M., van Erning, F. N., van der Geest, L. G., de Groot, J. W. B., Mohammad, N. H., Lemmens, V. E. P. P., van Laarhoven, H. W. M., Besselink, M. G., & Wilmink, J. W. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.008 · Cited by 55
Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Ganjoo, K. N., & Wakelee, H. A. (2007) · PubMed Central · Cited by 49
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer
Blanke, C. D., Beer, T. M., Todd, K., Mori, M., Stone, M. K., & Lopez, C. D. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9184-6 · Cited by 49
Borderline Resectable Pancreatic Cancer: On the Edge of Survival
Springett, G. M., & Hoffe, S. E. (2008) · Cancer Control · doi:10.1177/107327480801500404 · Cited by 49
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, H. M., Picozzi, V. J., Chandana, S. R., Melichar, B., Kasi, A., Gang, J., Gallego, J., Bullock, A., Chunyi, H., Wyrwicz, L. S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00746 · Cited by 56
Self-citation
Venous thromboembolism and cancer: a systematic review
Arrais‐Rodrigues, C., Ferrarotto, R., Filho, R. K., Novis, Y. A. S., & Hoff, P. M. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0441-0 · Cited by 47
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?
Kim, R. D. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70237-0 · Cited by 48
A Bayesian Meta-Analysis of Multiple Treatment Comparisons of Systemic Regimens for Advanced Pancreatic Cancer
Chan, K., Shah, K. T., Lien, K., Coyle, D., Lam, H., & Ko, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108749 · Cited by 48
Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies
Sutton, J. M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i42.15564 · Cited by 48
Nicotinamide prohibits proliferation and enhances chemosensitivity of pancreatic cancer cells through deregulating SIRT1 and Ras/Akt pathways
Zhang, J., Zhao, G., Qin, Q., Wang, B., Liu, L., Liu, Y., Deng, S., Tian, K., & Wang, C. (2013) · Pancreatology · doi:10.1016/j.pan.2013.01.001 · Cited by 48
Stromal Cell-Derived Factor 1α Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer
Weekes, C. D., Song, D., Arcaroli, J. J., Wilson, L. A., Rubio‐Viqueira, B., Cusatis, G., Garrett-Mayer, E. S., Messersmith, W. A., Winn, R. A., & Hidalgo, M. M. (2012) · Neoplasia · doi:10.1593/neo.111810 · Cited by 48
Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy
Tanaka, T., Ikeda, M., Okusaka, T., Ueno, H., Morizane, C., Hagihara, A., Iwasa, S., & Kojima, Y. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn098 · Cited by 48
Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Ayyappan, S. R., Prabhakar, D., & Sharma, N. (2013) · PubMed · Cited by 48
Hedgehog Signaling in Pancreatic Fibrosis and Cancer
Bai, Y., Bai, Y., Dong, J., Li, Q., Jin, Y., Chen, B., & Zhou, M. (2016) · Medicine · doi:10.1097/md.0000000000002996 · Cited by 47
How grim is pancreatic cancer?
Weledji, E. P., Enow-Orock, G. E., Mokake, M., & Sinju, M. (2016) · Oncology Reviews · doi:10.4081/oncol.2016.294 · Cited by 49
Long‐term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer: a multicenter prospective randomized controlled study
Jang, J., Kang, J. S., Han, Y., Heo, J. S., Choi, S. H., Choi, D. W., Park, S., Han, S., Yoon, D. S., Park, J. S., et al. (2017) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.465 · Cited by 48
Sitravatinib Sensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs
Wu, C., Hsiao, S.-H., Huang, Y.-H., Hung, L.-C., Yu, Y.-J., Chang, Y., Hung, T., & Wu, Y. (2020) · Cancers · doi:10.3390/cancers12010195 · Cited by 48
Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells
Tajima, K., Ohashi, R., Sekido, Y., Hida, T., Nara, T., Hashimoto, M., Iwakami, S., Minakata, K., Yae, T., Takahashi, F., et al. (2010) · Oncogene · doi:10.1038/onc.2009.478 · Cited by 48
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
Dragovich, T., Huberman, M. S., Hoff, D. D. V., Rowinsky, E. K., Nadler, P. I., Wood, D. L., Hamilton, M., Hage, G. P., Wolf, J. L., & Patnaik, A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0389-0 · Cited by 48
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU)
Hosen, S. M. Z., Uddin, M. N., Xu, Z., Buckley, B. J., Perera, C. J., Pang, T., Mekapogu, A. R., Moni, M. A., Notta, F., Gallinger, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1060957 · Cited by 50
Self-citation
Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
de Jesus, V. H. F., Mathias-Machado, M. C., de Farias, J. P. F., Aruquipa, M. P. S., Jacome, A. A. D. A., & Peixoto, R. D. (2023) · Cancers · doi:10.3390/cancers15205015 · Cited by 51
The war on cancer: are we winning?
Duffy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0759-2 · Cited by 47
Current and emerging therapies for the treatment of pancreatic cancer
Moss, R. A., & ', L. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s7203 · Cited by 47
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer
El-Khoueiry, A. B., Ramanathan, R. K., Yang, D., Zhang, W., Shibata, S., Wright, J. R., Gandara, D. R., & Lenz, H. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9658-9 · Cited by 47
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
Ioannou, N., Seddon, A. M., Dalgleish, A. G., Mackintosh, D., & Modjtahedi, H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-41 · Cited by 47
Association Between DNA-repair Polymorphisms and Survival in Pancreatic Cancer Patients Treated with Combination Chemotherapy
Giovannetti, E., Pacetti, P., Reni, M., León, L. G., Mambrini, A., Vasile, E., Ghidini, M., Funel, N., Lucchesi, M., Cereda, S., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.109 · Cited by 47
Pancreatic Proteolytic Enzyme Therapy Compared With Gemcitabine-Based Chemotherapy for the Treatment of Pancreatic Cancer
Chabot, J. A., Tsai, W., Fine, R. L., Chen, C., Kumah, C. K., Antman, K. H., & Grann, V. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8429 · Cited by 48
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer
Guo, J., Xie, K., & Zheng, S. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14995 · Cited by 47
Prognostic impact of carcinoembryonic antigen (CEA) on patients with metastatic pancreatic cancer: A retrospective cohort study
Imaoka, H., Mizuno, N., Hara, K., Hijioka, S., Tajika, M., Tanaka, T., Ishihara, M., Hirayama, Y., Hieda, N., Yoshida, T., et al. (2016) · Pancreatology · doi:10.1016/j.pan.2016.05.007 · Cited by 47
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
Wang, Y., Hu, G., Zhang, Q., Tang, N., Guo, J., Liu, L., Han, X., Wang, X., & Wang, Z. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s105442 · Cited by 47
Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective
Picozzi, V. J., Oh, S. Y., Edwards, A. M., Mandelson, M. T., Dorer, R. K., Rocha, F. G., Alseidi, A. A., Biehl, T. A., Traverso, L. W., Helton, W. S., et al. (2017) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5716-z · Cited by 47
Monoclonal Antibody L 1 Mab-13 Detected Human PD-L1 in Lung Cancers
Yamada, S., Itai, S., Nakamura, T., Yanaka, M., Chang, Y.-W., Suzuki, H., Kaneko, M. K., & Kato, Y. (2018) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0004 · Cited by 47
Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years
Hall, B. R., Cannon, A. C., Atri, P., Wichman, C., Smith, L. M., Ganti, A. K., Are, C., Sasson, A. R., Sushil Kumar, K., & Batra, S. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25036 · Cited by 47
Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma
Kenney, C. M., Kunst, T. F., Webb, S., DeVisser, C., Arrowood, C., Steinberg, S. M., Mettu, N. B., Kim, E. J.-H., & Rudloff, U. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01044-8 · Cited by 46
A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer
Ignatiadis, M., Polyzos, A., Stathopoulos, G. P., Tselepatiotis, E., Christophyllakis, C., Kalbakis, K., Vamvakas, L. N., Kotsakis, A. P., Potamianou, A., & Georgoulias, V. (2006) · Oncology · doi:10.1159/000106064 · Cited by 47
Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs
Zahorowska, B., Crowe, P. J., & Yang, J. (2009) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-009-0622-4 · Cited by 47
Next-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 49
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Thomas, G., Chardès, T., Gaborit, N., Mollévi, C., Leconet, W., Robert, B., Radosevic‐Robin, N., Penault-Llorca, F. M., Gongora, C., Colombo, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2231 · Cited by 46
Targeted Drug Delivery Systems for Pancreatic Cancer
Khare, V. R., Alam, N., Saneja, A., Dubey, R. D., & Gupta, P. N. (2014) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2014.2036 · Cited by 46
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
Hamilton, M., Wolf, J. L., Drolet, D. W., Fettner, S. H., Rakhit, A. K., Witt, K., & Lum, B. L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2390-3 · Cited by 47
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature
James, E. S., Waldron-Lynch, M., & Saif, M. W. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32832b511e · Cited by 46
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
on behalf of the Scottish Gynaecological Cancer Trials Group, Vasey, P. A., Gore, M. E., Wilson, R. H., Rustin, G. J. S., Gabra, H., Guastalla, J. P., Pujade-Lauraine, É., Paul, J., Carty, K., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604371 · Cited by 46
An overview of the epidermal growth factor receptor fluorescence in situ hybridisation challenge in tumour pathology
Martin, V., Mazzucchelli, L., & Frattini, M. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2008.059592 · Cited by 46
Current evidence for histone deacetylase inhibitors in pancreatic cancer
Koutsounas, I. S. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i6.813 · Cited by 47
KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy
Kullmann, F., Hartmann, A., Stöhr, R., Messmann, H., Dollinger, M. M., Trojan, J., Fuchs, M., Hollerbach, S., Harder, J., Troppmann, M., et al. (2011) · Oncology · doi:10.1159/000330194 · Cited by 46
Stem cells as the root of pancreatic ductal adenocarcinoma
Balic, A., Dorado, J., Alonso-Gómez, M., & Heeschen, C. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.11.007 · Cited by 49
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines
Mukai, S., Moriya, S., Hiramoto, M., Kazama, H., Kokuba, H., Che, X., Yokoyama, T., Sakamoto, S., Sugawara, A., Sunazuka, T., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3237 · Cited by 45
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer
Venkatasubbarao, K., Peterson, L. L., Zhao, S., Hill, P., Cao, L., Zhou, Q., Nawrocki, S. T., & Freeman, J. W. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-104 · Cited by 46
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
Goel, G., & Sun, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0141-5 · Cited by 46
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib
Faloppi, L., on behalf of the Italian Group for the Study of Digestive Tract Cancer (GISCAD), Bianconi, M., Giampieri, R., Sobrero, A. F., Labianca, R., Ferrari, D., Barni, S., Aitini, E., Zaniboni, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5197 · Cited by 46
Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC)
Er, J. L., Goh, P. N., Lee, C. Y., Tan, Y. J., Hii, L., Mai, C., Chung, F. F., & Leong, C. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1459-6 · Cited by 48
Therapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer
Javadinia, S. A., Shahidsales, S., Fanipakdel, A., Joudi‐Mashhad, M., Mehramiz, M., Talebian, S., Maftouh, M., Mardani, R., Hassanian, S. M., Khazaei, M., et al. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27835 · Cited by 46
Crosstalk between Epidermal Growth Factor Receptors (EGFR) and integrins in resistance to EGFR tyrosine kinase inhibitors (TKIs) in solid tumors
Javadi, S., Zhiani, M., Mousavi, M. A., & Fathi, M. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151083 · Cited by 44
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Anderson, M. G., Falls, H. D., Mitten, M. J., Oleksijew, A., Vaidya, K. S., Boghaert, E. R., Gao, W., Palma, J. P., Cao, D., Chia, P.-L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0149 · Cited by 47
Erlotinib in combination with capecitabine and docetaxel in patients with metastatic breast cancer: A dose-escalation study
Twelves, C. J., Trigo, J. M., Jones, R. J., Rosa, F. D., Rakhit, A. K., Fettner, S. H., Wright, T., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.011 · Cited by 46
Low Expression of Junctional Adhesion Molecule A Is Associated with Metastasis and Poor Survival in Pancreatic Cancer
Fong, D., Spizzo, G., Mitterer, M., Seeber, A., Steurer, M., Gastl, G. A., Brosch, I., & Moser, P. L. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2381-8 · Cited by 46
Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group
Lutz, M. P., Cutsem, E. V., Wagener, T., Laethem, J. V., Vanhoefer, U. J., Wils, J. A., Gamelin, E., Koehne, C. H., Arnaud, J. P., Mitry, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1980 · Cited by 46
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’
Haas, M., Siveke, J. T., Schenk, M., Lerch, M. M., Caca, K., Freiberg‐Richter, J., von Weikersthal, L. F., Kullmann, F., Reinacher-Schick, A. C., Fuchs, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.02.008 · Cited by 45
A FAM83A Positive Feed-back Loop Drives Survival and Tumorigenicity of Pancreatic Ductal Adenocarcinomas
Parameswaran, N., Bartel, C. A., Hernandez-Sanchez, W. M., Miskimen, K. L. S., Smigiel, J. M., Khalil, A. M., & Jackson, M. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49475-5 · Cited by 45
STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer
Li, X., Jiang, W., Dong, S., Li, W.-C., Zhu, W., & Zhou, W. (2022) · Biomolecules · doi:10.3390/biom12101450 · Cited by 41
Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib
Ge, W., Wang, Y., Quan, M., Mao, T., Bischof, E. Y., Xu, H., Zhang, X., Li, S., Yue, M., Ma, J., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01965-5 · Cited by 45
Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma
Conradt, L., Godl, K., Schaab, C., Tebbe, A., Eser, S., Diersch, S., Michalski, C. W., Kleeff, J. H., Schnieke, A., Schmid, R. M., et al. (2011) · Neoplasia · doi:10.1593/neo.111016 · Cited by 47
Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside
Furukawa, T. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2226-1 · Cited by 45
Molecular Pathogenesis and Targeted Therapy of Pancreatic Cancer
Tanaka, S. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4463-x · Cited by 45
Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cellsin vitroby inhibition of nuclear factor-κB activity
Du, Q. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i33.5485 · Cited by 45
Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine
Papademetrio, D. L., Cavaliere, V., Simunovich, T., Costantino, S. N., Campos, M., Lombardo, T., Kaiser, C. M. F., & Alvarez, E. E. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0278-5 · Cited by 46
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
Jesus‐Acosta, A. D., Oliver, G. R., Blackford, A. L., Kinsman, K., Flores, E. I., Wilfong, L. S., Zheng, L., Donehower, R. C., Cosgrove, D., Laheru, D. A., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1704-y · Cited by 45
Isolation of pancreatic cancer cells from a patient-derived xenograft model allows for practical expansion and preserved heterogeneity in culture
Pham, K., Delitto, D., Knowlton, A. E., Hartlage, E. R., Madhavan, R., Gonzalo, D. H., Thomas, R. M., Behrns, K. E., George, T. J., Hughes, S. J., et al. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2016.02.009 · Cited by 46

Authors: Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W.
Affiliations: Norton Healthcare (US)
From the Divisions of Medical Oncology, Hematology, and Surgical Oncology, Princess Margaret Hospital, Toronto; National Cancer Institute of Canada Clinical Trials Group, Kingston; Algoma District Cancer Program, Sault Ste Marie, Ontario; Cross Cancer Institute, Edmonton, Alberta, Canada; the Australasian Gastrointestinal Tumor Group, Sydney, Australia; Norton Healthcare Pavilion, Louisville, KY; UCLA Medical Center, Los Angeles, CA; M. D. Anderson Cancer Centre, Houston, TX; OSI Pharmaceuticals, Boulder...
ORCID: Moore, Malcolm J.
Goldstein, David
Hamm, John
Hecht, Joel R.
Au, Heather J.
Wolff, Robert A.
Ding, Keyue
Clark, Gary
Parulekar, Wendy
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2007-05-20
Volume: 25
Issue: 15
Pages: 1960-1966
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2006.07.9525
OpenAlex: W2158134441
Cited by: 3,848
References: 49
Citations by year: 2026: 45 · 2025: 62 · 2024: 123 · 2023: 113 · 2022: 129 · 2021: 178 · 2020: 159 · 2019: 170 · 2018: 204 · 2017: 217 · 2016: 242 · 2015: 275 · 2014: 274 · 2013: 251 · 2012: 268
FWCI: 133.78
Type: journal article
Language: en
Update notices: new_edition (2023-10-17)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: erlotinib, gemcitabine, advanced pancreatic cancer, targeted therapy, overall survival, progression-free survival, metastatic pancreatic cancer, combination chemotherapy, adverse events
MeSH terms: Erlotinib Hydrochloride, Gemcitabine, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Double-Blind Method, Female, Humans, International Agencies, Male, Middle Aged, Pancreatic Neoplasms, Placebos, Prognosis, Quinazolines, Survival Rate, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks